MM&M1h
BridgeBio’s stock rises on promising sales of recently approved heart drug
BridgeBio’s ATTR cardiomyopathy drug, Attruby, achieved promising sales numbers in the weeks after its FDA approval.
MM&M4h
Bärbel Egli-Unckrich
In an interview with Campaign Germany, the 80-year-old S4 Capital chief executive took aim at rivals, fielded questions about ...
MM&M4h
Backed by Recursion CEO, Altitude Lab venture aims to fill gap from NIH cuts
Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...
MM&M22h
Sir Martin Sorrell on ‘lack of strategy’ at Omnicom and why WPP should be ‘broken up’
In an interview with Campaign Germany, the 80-year-old S4 Capital chief executive took aim at rivals, fielded questions about his own holding company and made predictions about the future of adland.
MM&M22h
Republicans are eyeing cuts to Medicaid. What’s Medicaid, again?
Medicaid is complex. The $880 billion-a-year state-federal program offers health coverage to millions of disabled and ...
MM&M22h
Margaret Coker, The Current for ProPublica
By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions ...